Stéphanie Debette1,2, Sabrina Schilling1, Marie-Gabrielle Duperron1, Susanna C Larsson3,4, Hugh S Markus3. 1. University of Bordeaux, Inserm 1219, Bordeaux Population Health Research Center, Bordeaux, France. 2. Department of Neurology, Memory Clinic, Bordeaux University Hospital, Bordeaux, France. 3. Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom. 4. Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Abstract
Importance: Covert vascular brain injury (VBI) is highly prevalent in community-dwelling older persons, but its clinical and therapeutic implications are debated. Objective: To better understand the clinical significance of VBI to optimize prevention strategies for the most common age-related neurological diseases, stroke and dementia. Data Source: We searched for articles in PubMed between 1966 and December 22, 2017, studying the association of 4 magnetic resonance imaging (MRI) markers of covert VBI (white matter hyperintensities [WMHs] of presumed vascular origin, MRI-defined covert brain infarcts [BIs], cerebral microbleeds [CMBs], and perivascular spaces [PVSs]) with incident stroke, dementia, or death. Study Selection: Data were taken from prospective, longitudinal cohort studies including 50 or more adults. Data Extraction and Synthesis: We performed inverse variance-weighted meta-analyses with random effects and z score-based meta-analyses for WMH burden. The significance threshold was P < .003 (17 independent tests). We complied with the Meta-analyses of Observational Studies in Epidemiology guidelines. Main Outcomes and Measures: Stroke (hemorrhagic and ischemic), dementia (all and Alzheimer disease), and death. Results: Of 2846 articles identified, 94 studies were eligible, with up to 14 529 participants for WMH, 16 012 participants for BI, 15 693 participants for CMB, and 4587 participants for PVS. Extensive WMH burden was associated with higher risk of incident stroke (hazard ratio [HR], 2.45; 95% CI, 1.93-3.12; P < .001), ischemic stroke (HR, 2.39; 95% CI, 1.65-3.47; P < .001), intracerebral hemorrhage (HR, 3.17; 95% CI, 1.54-6.52; P = .002), dementia (HR, 1.84; 95% CI, 1.40-2.43; P < .001), Alzheimer disease (HR, 1.50; 95% CI, 1.22-1.84; P < .001), and death (HR, 2.00; 95% CI, 1.69-2.36; P < .001). Presence of MRI-defined BIs was associated with higher risk of incident stroke (HR, 2.38; 95% CI, 1.87-3.04; P < .001), ischemic stroke (HR, 2.18; 95% CI, 1.67-2.85; P < .001), intracerebral hemorrhage (HR, 3.81; 95% CI, 1.75-8.27; P < .001), and death (HR, 1.64; 95% CI, 1.40-1.91; P < .001). Presence of CMBs was associated with increased risk of stroke (HR, 1.98; 95% CI, 1.55-2.53; P < .001), ischemic stroke (HR, 1.92; 95% CI, 1.40-2.63; P < .001), intracerebral hemorrhage (HR, 3.82; 95% CI, 2.15-6.80; P < .001), and death (HR, 1.53; 95% CI, 1.31-1.80; P < .001). Data on PVS were limited and insufficient to conduct meta-analyses but suggested an association of high PVS burden with increased risk of stroke, dementia, and death; this requires confirmation. Conclusions and Relevance: We report evidence that MRI markers of VBI have major clinical significance. This research prompts careful evaluation of the benefit-risk ratio for available prevention strategies in individuals with covert VBI.
Importance: Covert vascular brain injury (VBI) is highly prevalent in community-dwelling older persons, but its clinical and therapeutic implications are debated. Objective: To better understand the clinical significance of VBI to optimize prevention strategies for the most common age-related neurological diseases, stroke and dementia. Data Source: We searched for articles in PubMed between 1966 and December 22, 2017, studying the association of 4 magnetic resonance imaging (MRI) markers of covert VBI (white matter hyperintensities [WMHs] of presumed vascular origin, MRI-defined covert brain infarcts [BIs], cerebral microbleeds [CMBs], and perivascular spaces [PVSs]) with incident stroke, dementia, or death. Study Selection: Data were taken from prospective, longitudinal cohort studies including 50 or more adults. Data Extraction and Synthesis: We performed inverse variance-weighted meta-analyses with random effects and z score-based meta-analyses for WMH burden. The significance threshold was P < .003 (17 independent tests). We complied with the Meta-analyses of Observational Studies in Epidemiology guidelines. Main Outcomes and Measures: Stroke (hemorrhagic and ischemic), dementia (all and Alzheimer disease), and death. Results: Of 2846 articles identified, 94 studies were eligible, with up to 14 529 participants for WMH, 16 012 participants for BI, 15 693 participants for CMB, and 4587 participants for PVS. Extensive WMH burden was associated with higher risk of incident stroke (hazard ratio [HR], 2.45; 95% CI, 1.93-3.12; P < .001), ischemic stroke (HR, 2.39; 95% CI, 1.65-3.47; P < .001), intracerebral hemorrhage (HR, 3.17; 95% CI, 1.54-6.52; P = .002), dementia (HR, 1.84; 95% CI, 1.40-2.43; P < .001), Alzheimer disease (HR, 1.50; 95% CI, 1.22-1.84; P < .001), and death (HR, 2.00; 95% CI, 1.69-2.36; P < .001). Presence of MRI-defined BIs was associated with higher risk of incident stroke (HR, 2.38; 95% CI, 1.87-3.04; P < .001), ischemic stroke (HR, 2.18; 95% CI, 1.67-2.85; P < .001), intracerebral hemorrhage (HR, 3.81; 95% CI, 1.75-8.27; P < .001), and death (HR, 1.64; 95% CI, 1.40-1.91; P < .001). Presence of CMBs was associated with increased risk of stroke (HR, 1.98; 95% CI, 1.55-2.53; P < .001), ischemic stroke (HR, 1.92; 95% CI, 1.40-2.63; P < .001), intracerebral hemorrhage (HR, 3.82; 95% CI, 2.15-6.80; P < .001), and death (HR, 1.53; 95% CI, 1.31-1.80; P < .001). Data on PVS were limited and insufficient to conduct meta-analyses but suggested an association of high PVS burden with increased risk of stroke, dementia, and death; this requires confirmation. Conclusions and Relevance: We report evidence that MRI markers of VBI have major clinical significance. This research prompts careful evaluation of the benefit-risk ratio for available prevention strategies in individuals with covert VBI.
Authors: David S Knopman; Michael E Griswold; Seth T Lirette; Rebecca F Gottesman; Kejal Kantarci; A Richey Sharrett; Clifford R Jack; Jonathan Graff-Radford; Andrea L C Schneider; B Gwen Windham; Laura H Coker; Marilyn S Albert; Thomas H Mosley Journal: Stroke Date: 2015-01-06 Impact factor: 7.914
Authors: N K J Oksala; A Oksala; T Pohjasvaara; R Vataja; M Kaste; P J Karhunen; T Erkinjuntti Journal: J Neurol Neurosurg Psychiatry Date: 2009-02-22 Impact factor: 10.154
Authors: Niels D Prins; Ewoud J van Dijk; Tom den Heijer; Sarah E Vermeer; Peter J Koudstaal; Matthijs Oudkerk; Albert Hofman; Monique M B Breteler Journal: Arch Neurol Date: 2004-10
Authors: Mariëlle M F Poels; Ewout W Steyerberg; Renske G Wieberdink; Albert Hofman; Peter J Koudstaal; M Arfan Ikram; Monique M B Breteler Journal: J Neurol Neurosurg Psychiatry Date: 2012-08-23 Impact factor: 10.154
Authors: Anil M Tuladhar; Ingeborg W M van Uden; Loes C A Rutten-Jacobs; Andrew Lawrence; Helena van der Holst; Anouk van Norden; Karlijn de Laat; Ewoud van Dijk; Jurgen A H R Claassen; Roy P C Kessels; Hugh S Markus; David G Norris; Frank-Erik de Leeuw Journal: Neurology Date: 2016-02-17 Impact factor: 9.910
Authors: Stéphanie Debette; Joshua C Bis; Myriam Fornage; Helena Schmidt; M Arfan Ikram; Sigurdur Sigurdsson; Gerardo Heiss; Maksim Struchalin; Albert V Smith; Aad van der Lugt; Charles DeCarli; Thomas Lumley; David S Knopman; Christian Enzinger; Gudny Eiriksdottir; Peter J Koudstaal; Anita L DeStefano; Bruce M Psaty; Carole Dufouil; Diane J Catellier; Franz Fazekas; Thor Aspelund; Yurii S Aulchenko; Alexa Beiser; Jerome I Rotter; Christophe Tzourio; Dean K Shibata; Maria Tscherner; Tamara B Harris; Fernando Rivadeneira; Larry D Atwood; Kenneth Rice; Rebecca F Gottesman; Mark A van Buchem; Andre G Uitterlinden; Margaret Kelly-Hayes; Mary Cushman; Yicheng Zhu; Eric Boerwinkle; Vilmundur Gudnason; Albert Hofman; Jose R Romero; Oscar Lopez; Cornelia M van Duijn; Rhoda Au; Susan R Heckbert; Philip A Wolf; Thomas H Mosley; Sudha Seshadri; Monique M B Breteler; Reinhold Schmidt; Lenore J Launer; W T Longstreth Journal: Stroke Date: 2009-12-31 Impact factor: 7.914
Authors: Adam de Havenon; Chelsea Meyer; J Scott McNally; Matthew Alexander; Lee Chung Journal: Curr Atheroscler Rep Date: 2019-07-27 Impact factor: 5.113
Authors: Rizwan Kalani; Traci M Bartz; Astrid Suchy-Dicey; Mitchell S V Elkind; Bruce M Psaty; Lester Y Leung; Kenneth Rice; David Tirschwell; W T Longstreth Journal: Stroke Date: 2019-12-17 Impact factor: 7.914
Authors: Eugene L Scharf; Jonathan Graff-Radford; Scott A Przybelski; Timothy G Lesnick; Michelle M Mielke; David S Knopman; Gregory M Preboske; Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Mary Machulda; Kejal Kantarci; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: Stroke Date: 2019-09-12 Impact factor: 7.914
Authors: Christoph Johannes Griessenauer; David McPherson; Andrea Berger; Ping Cuiper; Nelson Sofoluke; Matthew D Adams; Saran Kunaprayoon; Ramin Zand; Jiang Li; Vida Abedi; Oded Goren; Clemens M Schirmer; Kathleen Donahue; Marco Nardin; Anne-Karin Giese; Markus D Schirmer; Natalia S Rost; Philipp Hendrix Journal: Cerebrovasc Dis Date: 2020-07-21 Impact factor: 2.762